Olympus upgrades after Covid-19 recovery

Sales have increased in the US, Europe, and its homecountry of Japan, reports medtech company Olympus, as it upgrades its operating profit expectations for the next financial year.

Japanese Olympus, a competitor to Danish Ambu within the endoscope market, has upgraded its guidance for the skewed fiscal year 2021/2022. The Japenese company now thinks full-year operating profits of JPY 144bn (USD 1.27bn) are likely, up from JPY 140bn (USD 1.23bn).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs